This panel session will examine the implications of FDA’s December 2022 guidance for homeopathic products and the ongoing efforts and strategies employed by both the industry and FDA to ensure compliance and navigate the evolving regulatory landscape within this niche segment.

• Developing a comprehensive understanding of the nuanced regulatory environment in which homeopathic products operate
• Addressing notable actions taken by regulatory bodies in response to safety concerns, particularly highlighting FDA’s actions against injectable homeopathic drugs
• Gaining insights into the reclassification of homeopathic products as unapproved drugs and the resulting impact on the industry